Search

Your search keyword '"Zabana, Y."' showing total 276 results

Search Constraints

Start Over You searched for: Author "Zabana, Y." Remove constraint Author: "Zabana, Y."
276 results on '"Zabana, Y."'

Search Results

1. P829 Clostridioides difficile infection in patients using vedolizumab and antiTNF: incidence and consequences (CDIFVEDO study of GETECCU)

2. P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry

3. P168 Specialized pro-resolving lipid mediator Resolvin D1 and omega 6 dihomo-γ-linolenic acid are unable to solve inflammation in the creeping fat of patients with severe postoperative recurrence in Crohn's disease

4. OP37 Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU

5. P493 Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?

6. P081 The integration of transcriptomic and microbiomic data links several intestinal bacterial families with key biological functions in the development of postoperative recurrence in Crohn's disease

7. DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort

8. P989 Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU

9. P1115 Characteristics and management of pyoderma gangrenosum and erythema nodosum in patients with inflammatory bowel disease: PIONOSO multicenter study

10. P524 Etrasimod shows low risk of adverse events following concomitant use with opioids or antidepressants in patients with ulcerative colitis

11. P424 Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?

12. DOP17 HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry

13. P023 Immune-metabolic profiles of creeping fat in relation to degree of severity in Crohn's disease postsurgical recurrence

14. P327 Characteristics of esophago-gastro-duodenal Crohn's disease in the biologic era: a nationwide study of the Young GETECCU Group

15. OP26 Impact of telemonitoring on the management of Inflammatory Bowel Disease in Spain: a multicenter TECCU clinical trial

16. P625 Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitis

18. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

19. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study

20. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry

21. DOP016 Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study

22. Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

23. Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU)

25. Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)

26. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

27. Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU)

28. P349 Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU)

29. P371 The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study

31. P118 Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)

32. P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

33. DOP04 Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU)

34. Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu

36. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

37. Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

38. Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience

41. Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU

43. Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection

44. Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

45. Use of capsule endoscopy in inflammatory bowel disease in clinical practice in Spain. Results from a national survey

46. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients

47. Impact of biological agents on postoperative complications in inflammatory bowel disease: a multicentre study of GETECCU

49. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.

50. P104 Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU

Catalog

Books, media, physical & digital resources